Quantcast

Urticaria and angioedema in renal cell cancer patients treated with IL-2.

Research paper by Theodore F TF Logan, Giovanni G Strippoli, Macy I MI Levine

Indexed on: 14 Sep '07Published on: 14 Sep '07Published in: Cancer investigation



Abstract

Interleukin-2 therapy has produced significant improvement in a proportion of patients with renal cell cancer. Dermatologic side effects, such as erythema, have been very common. However, we could find only 2 reports of urticaria in the medical literature. Here, we report 8 patients with renal cell cancer who developed urticaria in association with interleukin-2 therapy. The hives tended to occur at the end of a treatment cycle. Skin tests with IL-2 were negative in two patients. Urticaria did not worsen or consistently occur with repeated courses of interleukin-2 and anaphylaxis was not observed in any patient. Six of the 8 patients previously had urticaria unrelated to IL-2 therapy.